IRadimed Corporation
IRMD · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.52 | -3.65 | 13.55 | 12.30 |
| FCF Yield | 0.65% | 0.09% | 0.42% | 0.80% |
| EV / EBITDA | 89.30 | 109.67 | 98.71 | 136.05 |
| Quality | ||||
| ROIC | 5.48% | 4.59% | 5.23% | 5.25% |
| Gross Margin | 78.17% | 76.08% | 76.13% | 77.44% |
| Cash Conversion Ratio | 1.25 | 1.34 | 0.92 | 1.16 |
| Growth | ||||
| Revenue 3-Year CAGR | 8.53% | 9.04% | 10.00% | 11.17% |
| Free Cash Flow Growth | 727.84% | -79.71% | -42.59% | -4.93% |
| Safety | ||||
| Net Debt / EBITDA | -6.69 | -8.94 | -7.96 | -11.95 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.40 | 0.44 | 0.44 | 0.37 |
| Cash Conversion Cycle | 236.05 | 212.20 | 214.40 | 265.35 |